These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 24122306)

  • 41. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on pulmonary arterial hypertension pharmacotherapy.
    Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
    Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacologic treatment of pulmonary arterial hypertension.
    Ramani GV; Gill S
    Curr Pharm Des; 2013; 19(22):3963-73. PubMed ID: 23228314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
    Wu S; Hoang HB; Yang JZ; Papamatheakis DG; Poch DS; Alotaibi M; Lombardi S; Rodriguez C; Kim NH; Fernandes TM
    Chest; 2022 Dec; 162(6):1360-1372. PubMed ID: 35841932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
    Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC; Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New pharmacotherapies for pulmonary hypertension: where do they fit in?
    Wolfson AM; Steiger N; Gomberg-Maitland M
    Curr Hypertens Rep; 2014 Dec; 16(12):496. PubMed ID: 25304107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Combination therapy in patients with pulmonary arterial hypertension].
    Ewert R; Opitz CF; Schäper C; Gläser S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical treatment update on pulmonary arterial hypertension.
    Enderby CY; Burger C
    Ther Adv Chronic Dis; 2015 Sep; 6(5):264-72. PubMed ID: 26336595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostacyclin therapy for pulmonary arterial hypertension.
    Ruan CH; Dixon RA; Willerson JT; Ruan KH
    Tex Heart Inst J; 2010; 37(4):391-9. PubMed ID: 20844610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.